For media inquiries, please email us at media@lyciatx.com May 13, 2024Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the ClinicDownload PDFRead MoreJune 05, 2023Lycia Therapeutics to Present at Jefferies Healthcare ConferenceDownload PDFRead MoreOctober 05, 2022Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in ChemistryDownload PDFRead MoreFebruary 25, 2022Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific OfficerDownload PDFRead MoreSeptember 09, 2021Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant VenturesDownload PDFRead MoreAugust 25, 2021Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) DegradersDownload PDFRead MoreJune 09, 2020Versant Ventures Launches Lycia Therapeutics with $50 MillionDownload PDFRead More
